Publikationen, an denen er mitarbeitet Alejandro Balsa Criado (57)

2023

  1. Recommendations by the Spanish Society of Rheumatology on risk management of biological treatment and JAK inhibitors in patients with rheumatoid arthritis

    Reumatologia Clinica, Vol. 19, Núm. 10, pp. 533-548

2021

  1. Role of MUC1 rs4072037 polymorphism and serum KL-6 levels in patients with antisynthetase syndrome

    Scientific Reports, Vol. 11, Núm. 1

2020

  1. A cross-disease meta-GWAS identifies four new susceptibility loci shared between systemic sclerosis and Crohn’s disease

    Scientific Reports, Vol. 10, Núm. 1

  2. Influence of MUC5B gene on antisynthetase syndrome

    Scientific Reports, Vol. 10, Núm. 1

2019

  1. Evaluation of 12 GWAS-drawn SNPs as biomarkers of rheumatoid arthritis response to TNF inhibitors. A potential SNP association with response to etanercept

    PLoS ONE, Vol. 14, Núm. 2

  2. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring in clinical practice: the spanish cohort of the COMORA study

    Reumatologia Clinica, Vol. 15, Núm. 2, pp. 102-108

  3. Reducing or Maintaining the Dose of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis in Clinical Remission: A Randomized, Open-Label Trial

    Arthritis and Rheumatology, Vol. 71, Núm. 10, pp. 1616-1625

2018

  1. Validation study of genetic biomarkers of response to TNF inhibitors in rheumatoid arthritis

    PLoS ONE, Vol. 13, Núm. 5

2017

  1. A combined large-scale meta-Analysis identifies COG6 as a novel shared risk locus for rheumatoid arthritis and systemic lupus erythematosus

    Annals of the Rheumatic Diseases, Vol. 76, Núm. 1, pp. 286-294

  2. REDOSER project: optimising biological therapy dose for rheumatoid arthritis and spondyloarthritis patients

    Heliyon, Vol. 3, Núm. 11

2016

  1. Brief Report: IRF4 Newly Identified as a Common Susceptibility Locus for Systemic Sclerosis and Rheumatoid Arthritis in a Cross-Disease Meta-Analysis of Genome-Wide Association Studies

    Arthritis and Rheumatology, Vol. 68, Núm. 9, pp. 2338-2344

  2. Replication of PTPRC as genetic biomarker of response to TNF inhibitors in patients with rheumatoid arthritis

    Pharmacogenomics Journal, Vol. 16, Núm. 2, pp. 137-140

2015

  1. Actualización 2014 del Documento de Consenso de la Sociedad Española de Reumatología sobre el uso de terapias biológicas en la artritis reumatoide

    Reumatologia Clinica, Vol. 11, Núm. 5, pp. 279-294

  2. Lack of association between JAK3 gene polymorphisms and cardiovascular disease in Spanish patients with rheumatoid arthritis

    BioMed Research International, Vol. 2015

  3. Rheumatoid arthritis response to treatment across IgG1 allotype - anti-TNF incompatibility: A case-only study

    Arthritis Research and Therapy, Vol. 17, Núm. 1

2014

  1. Interferon regulatory factor 5 genetic variants are associated with cardiovascular disease in patients with rheumatoid arthritis

    Arthritis Research and Therapy, Vol. 16, Núm. 4

  2. Lack of association between ABO, PPAP2B, ADAMST7, PIK3CG, and EDNRA and carotid intima-media thickness, carotid plaques, and cardiovascular disease in patients with rheumatoid arthritis

    Mediators of Inflammation, Vol. 2014

  3. Lack of replication of interactions between polymorphisms in rheumatoid arthritis susceptibility: Case-control study

    Arthritis Research and Therapy, Vol. 16, Núm. 1

  4. Lack of validation of genetic variants associated with anti-tumor necrosis factor therapy response in rheumatoid arthritis: A genome-wide association study replication and meta-analysis

    Arthritis Research and Therapy, Vol. 16, Núm. 2

  5. Osteoprotegerin CGA haplotype protection against cerebrovascular complications in anti-CCP negative patients with rheumatoid arthritis

    PLoS ONE, Vol. 9, Núm. 9